Ignite Creation Date:
2025-12-24 @ 10:29 PM
Ignite Modification Date:
2025-12-29 @ 9:08 PM
Study NCT ID:
NCT06082635
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-18
First Post:
2023-10-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor:
Shenzhen TargetRx, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-14
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-08
First Submit QC Date:
None
Study First Post Date:
2023-10-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-16
Last Update Post Date:
2025-05-18
Last Update Post Date Type:
ACTUAL